Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long term changes in bone mineral density and fracture risk in patients receiving androgen deprivation therapy [bicalutamide, goserelin] for advanced prostate cancer, with stratification of treatment based on presenting values

Trial Profile

Long term changes in bone mineral density and fracture risk in patients receiving androgen deprivation therapy [bicalutamide, goserelin] for advanced prostate cancer, with stratification of treatment based on presenting values

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2007

At a glance

  • Drugs Bicalutamide (Primary) ; Goserelin (Primary)
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top